Replies to post #577778 on NorthWest Biotherapeutics Inc (NWBO)

[iwasadiver]

The slide shows DC vaccine plus placebo, plus Poly ICLC, plus Resiquimod (also a Toll-like-receptor agonist like Poly ICLC, just different receptor ligand). The graph shows 50% survival at 100 months (8+ years). Dr. Liau would like to obviously expand these trials using different dosing, etc. and go on to a registration trial with NWBO for approvals